Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

NCT05904119 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT05904119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05904119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 3
Overall status
Recruiting
Start date
March 15, 2024
Completion date
February 29, 2028
Enrollment
411 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

first progression of glioblastoma